Pauleit Dirk, Stoffels Gabriele, Bachofner Ansgar, Floeth Frank W, Sabel Michael, Herzog Hans, Tellmann Lutz, Jansen Paul, Reifenberger Guido, Hamacher Kurt, Coenen Heinz H, Langen Karl-Josef
Institute of Neuroscience and Medicine, Forschungszentrum Jülich, D-52425 Jülich, Germany.
Nucl Med Biol. 2009 Oct;36(7):779-87. doi: 10.1016/j.nucmedbio.2009.05.005. Epub 2009 Jul 29.
The purpose of this study was to compare the diagnostic value of positron emission tomography (PET) using [(18)F]-fluorodeoxyglucose ((18)F-FDG) and O-(2-[(18)F]fluoroethyl)-l-tyrosine ((18)F-FET) in patients with brain lesions suspicious of cerebral gliomas.
Fifty-two patients with suspicion of cerebral glioma were included in this study. From 30 to 50 min after injection of 180 MBq (18)F-FET, a first PET scan ((18)F-FET scan) was performed. Thereafter, 240 MBq (18)F-FDG was injected and a second PET scan was acquired from 30 to 60 min after the second injection ((18)F-FET/(18)F-FDG scan). The cerebral accumulation of (18)F-FDG was calculated by decay corrected subtraction of the (18)F-FET scan from the (18)F-FET/(18)F-FDG scan. Tracer uptake was evaluated by visual scoring and by lesion-to-background (L/B) ratios. The imaging results were compared with the histological results and prognosis.
Histology revealed 24 low-grade gliomas (LGG) of World Health Organization (WHO) Grade II and 19 high-grade gliomas (HGG) of WHO Grade III or IV, as well as nine others, mainly benign histologies. The gliomas showed increased (18)F-FET uptake (>normal brain) in 86% and increased (18)F-FDG uptake (>white matter) in 35%. (18)F-FET PET provided diagnostically useful delineation of tumor extent while this was impractical with (18)F-FDG due to high tracer uptake in the gray matter. A local maximum in the tumor area for biopsy guidance could be identified with (18)F-FET in 76% and with (18)F-FDG in 28%. The L/B ratios showed significant differences between LGG and HGG for both tracers but considerable overlap so that reliable preoperative grading was not possible. A significant correlation of tracer uptake with overall survival was found with (18)F-FDG only. In some benign lesions like abscesses, increased uptake was observed for both tracers indicating a limited specificity of both techniques.
(18)F-FET PET is superior to (18)F-FDG for biopsy guidance and treatment planning of cerebral gliomas. The uptake of (18)F-FDG is associated with prognosis, but the predictive value is limited and a histological evaluation of tumor tissue remains necessary. Therefore, amino acids like (18)F-FET are the preferred PET tracers for the clinical management of cerebral gliomas.
本研究的目的是比较使用[(18)F] - 氟脱氧葡萄糖((18)F - FDG)和O - (2 - [(18)F]氟乙基) - L - 酪氨酸((18)F - FET)的正电子发射断层扫描(PET)对疑似脑胶质瘤脑病变患者的诊断价值。
本研究纳入了52例疑似脑胶质瘤患者。在注射180 MBq(18)F - FET后30至50分钟,进行首次PET扫描((18)F - FET扫描)。此后,注射240 MBq(18)F - FDG,并在第二次注射后30至60分钟进行第二次PET扫描((18)F - FET/(18)F - FDG扫描)。通过对(18)F - FET/(18)F - FDG扫描进行衰变校正后减去(18)F - FET扫描来计算(18)F - FDG的脑内积聚。通过视觉评分和病变与背景(L/B)比值评估示踪剂摄取。将成像结果与组织学结果及预后进行比较。
组织学显示24例世界卫生组织(WHO)二级低级别胶质瘤(LGG)和19例WHO三级或四级高级别胶质瘤(HGG),以及其他9例,主要为良性组织学类型。胶质瘤中86%显示(18)F - FET摄取增加(>正常脑),35%显示(18)F - FDG摄取增加(>白质)。(18)F - FET PET能够提供对肿瘤范围的诊断性有用的描绘,而由于灰质中示踪剂摄取高,(18)F - FDG则无法做到这一点。76%的肿瘤区域可通过(18)F - FET确定活检引导的局部最大值,28%可通过(18)F - FDG确定。两种示踪剂的L/B比值在LGG和HGG之间均显示出显著差异,但有相当大的重叠,因此无法进行可靠的术前分级。仅发现(18)F - FDG的示踪剂摄取与总生存期有显著相关性。在一些良性病变如脓肿中,两种示踪剂均观察到摄取增加,表明两种技术的特异性有限。
(18)F - FET PET在脑胶质瘤的活检引导和治疗规划方面优于(18)F - FDG。(18)F - FDG的摄取与预后相关,但预测价值有限,肿瘤组织的组织学评估仍然必要。因此,像(18)F - FET这样的氨基酸是脑胶质瘤临床管理中首选的PET示踪剂。